Brachytherapy is associated with higher survival in gynecologic rhabdomyosarcoma

Five-year survival was 80% with brachytherapy-containing treatment versus 56% with EBRT alone, although substantial differences in patient selection limit interpretation.

KEY POINTS

  • This retrospective National Cancer Database (NCDB) study evaluated 290 patients with gynecologic rhabdomyosarcoma treated with chemotherapy and radiotherapy between 2004 and 2022. Of these, 74 received brachytherapy-containing regimens, including 18 receiving both brachytherapy and EBRT, while 216 received EBRT alone. The cohort included 153 pediatric patients (53%) and 137 adults (47%), with a median age of 16 years and median follow-up of approximately 46 months.
  • Treatment groups differed substantially in tumor site, histology, and surgical management. Vaginal tumors accounted for 31% of brachytherapy cases versus 8% of EBRT cases, while alveolar histology was present in only 2% versus 32%, respectively. Surgery or debulking was performed in approximately 85% of brachytherapy patients versus 56% receiving EBRT alone (p<0.01). Furthermore, tumors classified as pelvic, not otherwise specified, represented 12% of the brachytherapy group versus 64% of the EBRT group, illustrating substantial heterogeneity in the underlying disease populations.
  • Multivariable logistic regression identified several factors associated with brachytherapy selection. Vaginal tumor location was the strongest predictor (OR 8.10, 95% CI 3.33–20.7; p<0.001), followed by prior surgical treatment (OR 2.68, 95% CI 1.17–6.65; p=0.026). Later diagnosis year (OR 1.10 per year; p=0.003) and increasing age (OR 1.02 per year; p=0.004) were also associated with brachytherapy utilization, whereas alveolar histology strongly predicted selection of EBRT alone (OR for brachytherapy 0.18, 95% CI 0.03–0.68; p=0.027).
  • Overall survival was higher among patients receiving brachytherapy-containing regimens. Kaplan–Meier estimates demonstrated one-year OS of 97% versus 94% (p=0.001), three-year OS of 84% versus 68% (p=0.002), and five-year OS of 80% versus 56% (p=0.003) for brachytherapy and EBRT alone, respectively. The five-year absolute survival difference was 24 percentage points. After adjustment for age group, histology, prior surgery, and comorbidity, brachytherapy remained associated with lower mortality (adjusted HR 0.47, 95% CI 0.26–0.85; p=0.013).
  • The survival association was observed in both pediatric and adult subgroups. Among 153 pediatric patients, five-year OS was 95% with brachytherapy versus 66% with EBRT alone (p=0.01), while among 137 adults, corresponding survival was 68% versus 42% (p=0.02). Among patients undergoing surgery, brachytherapy was associated with improved OS (HR 0.50, 95% CI 0.26–0.96; p=0.038), whereas the association was not statistically significant among patients without surgery (HR 0.26, 95% CI 0.06–1.17; p=0.08). These subgroup findings remain observational and potentially affected by selection bias.
  • Radiation exposure was broadly comparable in reported EQD2, with median values of 43.5 Gy for brachytherapy-containing treatment versus 42.6 Gy for EBRT alone (p=0.16). However, radiation treatment duration was markedly shorter with brachytherapy, at a median 15 versus 39 days (p<0.001). Treatment schedules were heterogeneous, and the NCDB did not consistently capture detailed fractionation, subsequent radiation courses, or the precise contribution of brachytherapy versus EBRT within combined regimens.
  • The apparent survival advantage cannot be confidently attributed to brachytherapy itself. Patients selected for brachytherapy had substantially more favorable histological and surgical characteristics, while critical prognostic variables, including tumor size, disease stage, nodal involvement, metastatic status, and detailed chemotherapy regimens, were incomplete or unavailable. The database also lacked local control, disease-specific survival, treatment-related toxicity, functional outcomes, and organ-preservation endpoints, preventing direct evaluation of the proposed normal-tissue and functional advantages of brachytherapy.

CLINICAL TAKEAWAY

Brachytherapy-containing regimens were associated with substantially higher overall survival than EBRT alone in this national cohort of gynecologic rhabdomyosarcoma, supporting their continued consideration in anatomically suitable patients, particularly when localized treatment and organ preservation are priorities. However, strong differences in disease characteristics and surgical selection prevent the observed survival advantage from being interpreted as proof of brachytherapy superiority, and prospective or carefully controlled comparative data are needed.

SOURCE

Brachytherapy

Browse more research Suggest a correction